# Clinical Trials Data KIT - Document 23

# Rapid Urease Test for Diagnosis of H. Pylori Infection in Patients With Peptic Ulcer Bleeding

## Clinical Trial: https://clinicaltrials.gov/study/NCT01282853

"eligibilityCriteria": "Inclusion Criteria:\n\n\* gastroduodenal ulcer with bleeding, documented by endoscopic examination\n\nExclusion Criteria:\n\n\* 1. receiving continuous proton pump inhibitor treatment, antibiotics within 4 weeks 2. not suitable for endoscopic biopsy 3. hemodynamically unstable",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
]

Question:  
Based on the following clinical trial information, would a patient with a KIT gene mutation be eligible for the clinical trial?

Answer:  
This trial is for bleeding gastroduodenal ulcers. The information provided does \*not\* mention KIT gene mutations as either an inclusion or exclusion criteria. Therefore, having a KIT gene mutation \*\*doesn't automatically disqualify\*\* a patient.  
  
However, the patient still needs to meet \*all\* other inclusion criteria (bleeding gastroduodenal ulcer confirmed by endoscopy) and \*none\* of the exclusion criteria (recent PPI/antibiotic use, unsuitable for biopsy, hemodynamically unstable). If they meet those criteria, the KIT mutation shouldn't be a barrier to entry.